Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 40% of the UK-based firm's revenue comes from orthopedic products, and another 31% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the US, just over 30% is from other developed markets, and emerging markets account for the remainder.
Last trade$30.56
Day change-$0.41 (-1.32%)
Day range$30.49 – $31.08
Volume916,003
Market cap$12.95B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for SNN.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for SNN.
Recent news
Company coverage with links to the original publishers.
Smith+Nephew announced the European commercial launch of its CARTIHEAL AGILI-C Cartilage Repair Implant across 12 key markets, expanding its Sports Medicine portfolio. The product is backed by clinical evidence showing superior knee outcomes and pain relief over five years. The global cartilage repair market is projected to grow from $5.98 billion in 2024 to $8.04 billion by 2030 at a 5.1% CAGR.
Smith+Nephew announced the commercial availability of its CARTIHEAL AGILI-C cartilage repair implant in Europe, following its 2024 US launch. The aragonite-based implant demonstrated clinical superiority over standard care in a multicenter randomized controlled trial, showing superior pain relief and functional gains over 5 years. The product will initially be available in 12 European countries.
Smith+Nephew announced the commercial launch of CARTIHEAL AGILI-C, an innovative cartilage repair implant, across Europe. The aragonite-based scaffold will be presented at the ICRS Summit in Portugal (October 8-10). A randomized controlled trial published in the American Journal of Sports Medicine demonstrated clinical superiority over standard surgical care, with patients showing improved pain relief and functional outcomes over 5 years. The implant will initially be available in 8 European countries with plans for further expansion.
Smith+Nephew (SNN) launched the EVOS PELVIC Plating System to expand its orthopedic trauma portfolio into pelvic and acetabular fracture management. The system features dedicated plates, cannulated screws, and specialized instruments designed to improve surgical efficiency. The global pelvic trauma market is projected to grow from $2.81 billion in 2025 to $4.79 billion by 2034 at a 6.1% CAGR, driven by increased high-energy fractures and wider adoption of surgical fixation protocols.
The AI in orthopedic surgery market is experiencing remarkable growth with a projected CAGR of 27.2% through 2030. Key drivers include rising musculoskeletal disorders, AI-assisted surgical planning, robotic surgical systems integration, and enhanced implant placement precision. North America leads the market, while Asia-Pacific and Europe show growing segments despite tariff-related challenges.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Oct 2, 2026
$0.312
Nov 6, 2026
recurring
Mar 27, 2026
$0.482
May 27, 2026
recurring
Oct 3, 2025
$0.30
Nov 7, 2025
recurring
Mar 28, 2025
$0.462
May 28, 2025
recurring
Oct 4, 2024
$0.288
Nov 8, 2024
recurring
Stock splits
Historical share-structure events and their execution dates.